Core Viewpoint - The article discusses the serious disciplinary violations and illegal activities of Chen Shifei, former Deputy Director of the National Medical Products Administration, leading to his expulsion from the Communist Party and legal consequences [2][3][4]. Group 1: Disciplinary Violations - Chen Shifei lost his ideals and beliefs, resisted organizational review, and violated the spirit of the Central Eight Regulations by accepting gifts, cash, and consumption cards [2][3]. - He engaged in profit-making activities against regulations, including private lending for substantial returns and conducting business related to his former position after retirement [2][3]. Group 2: Legal Consequences - Chen Shifei was found to have committed serious violations of political, organizational, and ethical disciplines, constituting severe job-related misconduct and suspected bribery [3]. - The Central Commission for Discipline Inspection decided to expel him from the Party, cancel his benefits, confiscate his illegal gains, and transfer his case to the judicial authorities for prosecution [3][4]. Group 3: Professional Background - Chen Shifei was born in July 1962 in Zhejiang and had a career spanning various roles in pharmaceutical management, culminating in his position as Deputy Director of the National Medical Products Administration in September 2018 [4].

Core Viewpoint - The article emphasizes the significant therapeutic potential of Semaglutide for patients with type 2 diabetes and peripheral artery disease (PAD), highlighting its multifaceted benefits beyond glucose control and weight loss [3][10]. Research Objectives - The study aims to analyze whether the efficacy of Semaglutide is consistent across different clinical characteristics in patients with type 2 diabetes and PAD, focusing on key variables such as diabetes duration, body mass index (BMI), HbA1c levels, and concurrent medication use [5][8]. Research Methodology - The STRIDE trial included 792 patients with symptomatic PAD and type 2 diabetes, employing a randomized, double-blind design over 52 weeks to assess the effects of Semaglutide compared to a placebo [7]. Key Assessment Indicators - The primary endpoint was the improvement in maximum walking distance (MWD) after 52 weeks, with supplementary assessments of pain-free walking distance (PFWD) [9]. Research Results - Semaglutide significantly improved both MWD and PFWD across various patient subgroups, indicating a stable therapeutic effect regardless of patient characteristics [10][12]. - The average weight loss was 4.09 kg, and HbA1c levels decreased by 0.99%, but the benefits for PAD appeared to operate through independent mechanisms [11][12]. Safety Profile - The safety profile of Semaglutide was found to be comparable to that of the placebo, with no new safety concerns identified, and common gastrointestinal reactions and hypoglycemia were evenly distributed among subgroups [13]. Conclusion - Semaglutide is positioned as a breakthrough treatment option for patients with type 2 diabetes and PAD, demonstrating efficacy that extends beyond traditional mechanisms, including improvements in endothelial function and anti-inflammatory effects [16].

Core Viewpoint - The article emphasizes the urgent need for weight management in China, highlighting the government's commitment to addressing obesity through the "Weight Management Year" initiative as part of the "Healthy China 2030" strategy [4][11][14]. Group 1: Government Initiatives - The National Health Commission announced plans to achieve full coverage of weight management clinics in hospitals by June 2025, encouraging the establishment of obesity prevention centers [4][11]. - The recent surge in patients seeking weight management services reflects a growing societal awareness and urgency regarding obesity and its health implications [4][11]. Group 2: Expert Opinions - Experts like Ma Guansheng stress the importance of addressing obesity as a public health crisis, warning of significant economic and health burdens if not managed promptly [5][11]. - The article discusses the challenges of lifestyle interventions for weight management, noting that while medical advice is available, long-term success relies heavily on individual commitment [7][10]. Group 3: Societal Factors - The article highlights that obesity is often perceived as a personal issue rather than a public health concern, complicating efforts to address it [7][10]. - Factors such as sedentary lifestyles, work-related stress, and societal pressures contribute to the rising obesity rates, particularly among men and women [9][10]. Group 4: Future Directions - The article suggests that improving public health requires a multi-faceted approach, including better access to healthy food options and more opportunities for physical activity [13][14]. - There is a call for stronger government oversight and accountability in implementing health policies aimed at reducing obesity rates among children and adolescents [13][14].

Core Viewpoint - Novo Nordisk has lowered its full-year sales and profit forecasts due to slowing growth of its main drugs in the U.S. market, alongside the appointment of a new CEO, Maziar Mike Doustdar, following the unexpected dismissal of Lars Fruergaard Jørgensen in May [2][4]. Group 1: Financial Forecast Adjustments - The company now expects sales growth for the year to be between 8% and 14% on a constant currency basis, down from the previous forecast of 13% to 21% [4]. - Operating profit growth expectations have been revised from 16% to 24% down to 10% to 16% [4]. Group 2: Market Challenges - The downward adjustment in performance is primarily attributed to weak sales prospects for Wegovy and Ozempic in the U.S. market during the second half of the year [5]. - The company noted that the adjustment for Wegovy's sales expectations in the U.S. is due to the widespread use of combination therapies of semaglutide, slower-than-expected market expansion, and increased competition [5][6]. Group 3: Competitive Landscape - Novo Nordisk has faced challenges in the U.S. Wegovy market, particularly due to intensified competition from semaglutide combination therapies, which gained popularity following FDA rulings related to drug shortages [6]. - Despite previous statements indicating that regulatory measures could reduce the supply of these generic drugs in the second half of the year, disappointing clinical trial results, especially for the new obesity treatment candidate CagriSema, have further weakened market confidence in the growth prospects of its obesity treatment product line [7].

Core Viewpoint - The article discusses the implications of pausing the use of semaglutide and provides guidance on how to do so safely while maintaining weight management and health benefits [2]. Summary by Sections Timeline: What Happens After Injecting Semaglutide - 1-2 hours: The drug begins to be absorbed into the bloodstream after subcutaneous injection [6]. - 24-48 hours: Peak concentration in the blood is reached, actively binding to GLP-1 receptors [7]. - 1-2 weeks: Initial noticeable effects such as reduced appetite and improved blood sugar regulation may begin [8]. - 4-5 weeks: Steady state levels are achieved, leading to more pronounced appetite suppression and accelerated weight loss [9]. Best Way to Pause Medication - It is recommended to start with the lowest dose and gradually increase it over months to minimize potential side effects. Sudden discontinuation does not typically cause withdrawal symptoms [10]. - Gradually reducing the dose is advised to mitigate increased hunger that may occur after stopping the medication [12]. - Adjusting injection intervals can help manage the pause: minimum 2 days between injections or less than 12 days for extending the cycle [12]. Effects After Stopping Medication - A 2021 clinical trial showed that participants lost an average of 10.6% of their weight during treatment, but those switched to a placebo regained an average of 6.9% of their weight, while those continuing semaglutide lost an additional 7.9% [13]. - An observational study indicated that 18% of patients regained their lost weight after one year off the medication, with 26% regaining over 25% of their lost weight [13]. Importance of Continuing Medication - The STEP 5 trial demonstrated that continuous use of semaglutide for 2 years resulted in a weight loss of 15.2% compared to placebo, with 77.1% of patients losing at least 5% of their weight [16]. - The SELECT trial showed that patients maintained an average weight loss of about 10% over 4 years, emphasizing the chronic nature of obesity and the need for long-term management [16]. Obesity as a Chronic Disease - Recent studies confirm obesity as a chronic disease, with 76.8% of patients and 94.6% of doctors agreeing on its classification [17]. - Obesity leads to various health issues, increasing the risk of type 2 diabetes and cardiovascular diseases, necessitating its inclusion in chronic disease management [17]. Weight Loss and Chronic Complications - Weight loss of 5% can improve hypertension and blood sugar levels, while a 10-15% reduction significantly lowers risks associated with cardiovascular diseases and diabetes [19]. - Overall, weight loss interventions can substantially reduce the risk of chronic complications and improve health outcomes for obese patients [19].

Core Viewpoint - GLP-1 drugs, initially developed for blood sugar and weight control, have shown potential in treating various chronic diseases, including cardiovascular diseases, chronic kidney disease, fatty liver, arthritis, and sleep apnea, with benefits stemming from their anti-inflammatory and metabolic regulatory mechanisms, some of which are independent of weight loss [2]. Group 1: Multiple Efficacies of Modern GLP-1 Drugs - Modern GLP-1 receptor agonists, such as liraglutide, dulaglutide, semaglutide, and dual agonists like tirzepatide, were initially used for type 2 diabetes (T2D) treatment, promoting insulin secretion and appetite suppression [3]. - Liraglutide, semaglutide, and tirzepatide are now approved for treating obesity or overweight individuals with at least one related disease [3]. Group 2: Broad Benefits Beyond Glycemic Control and Weight Loss - GLP-1 drugs significantly reduce the risk of chronic kidney disease (CKD), myocardial infarction, stroke, and cardiovascular mortality, particularly in patients with obesity and/or T2D [5]. Group 3: Cardiovascular and Renal Protective Effects - In 2024, semaglutide became the first FDA-approved drug for weight loss that also reduces cardiovascular event risks in non-T2D patients with obesity or overweight and cardiovascular disease risk [6]. - The SELECT trial showed that semaglutide reduced the incidence of major adverse cardiovascular events (MACE) by 20%, independent of weight loss [6]. - The FLOW trial indicated that semaglutide reduced significant adverse events related to kidney function deterioration by 24% over 3.4 years in T2D and CKD patients [6]. Group 4: Efficacy Against Metabolic Fatty Liver Disease - A 240-week phase 3 trial showed that 63% of patients with moderate to severe liver fibrosis achieved fatty liver inflammation resolution after 72 weeks of semaglutide treatment, with significant improvement in fibrosis compared to placebo [10]. Group 5: Improvements in Arthritis and Sleep Apnea - The STEP 9 trial demonstrated significant improvement in joint pain scores among participants with moderate knee osteoarthritis after 68 weeks of semaglutide treatment, with a weight loss of 13.7% [11]. - Tirzepatide was approved for treating moderate to severe obstructive sleep apnea (OSA) in 2024, showing significant reductions in apnea/hypopnea events [11]. Group 6: Efficacy in Peripheral Artery Disease - The STRIDE trial evaluated semaglutide's efficacy in T2D patients with intermittent claudication, showing significant improvement in maximum walking distance compared to placebo [12]. Group 7: Neuroprotective Potential and Inflammatory Mechanisms - Large clinical trials have found that GLP-1 drugs can reduce stroke risk, potentially through improved metabolism, central inflammation regulation, and enhanced vascular function [13]. - Ongoing trials are investigating the effects of oral semaglutide on early Alzheimer's disease, with results expected in 2025 [14]. Group 8: Potential Independent of Weight Loss - The therapeutic effects of GLP-1 drugs in various chronic diseases may not solely depend on weight loss, as they can significantly lower inflammatory markers independent of weight reduction [15]. - The anti-inflammatory mechanisms of GLP-1 drugs may involve direct action on GLP-1 receptor-positive cells and immune cells, indirect improvement of inflammation through weight loss and blood sugar control, and activation of specific neuronal populations in the central nervous system [15]. Group 9: Outlook and Future Directions - The benefits of GLP-1 drugs have expanded beyond glycemic control and weight loss to include multiple systemic diseases, with ongoing research exploring their effects on addiction, mental health, and neurodegenerative diseases [16]. - Future research should focus on ideal dosing in non-obese populations, potential use of lower doses in non-metabolic diseases, and identifying signaling pathways independent of weight loss [16].

Core Viewpoint - The article emphasizes the urgent need for weight management in China, highlighting the alarming obesity rates and associated health risks, which have prompted the government to implement a three-year action plan to combat this issue [4][10][25]. Summary by Sections Obesity Impact - As of 2021, China has the highest number of overweight and obese individuals globally, with 402 million people aged 25 and above affected [5]. - Obesity is linked to over 200 diseases, including type 2 diabetes, hypertension, and various cancers, contributing to over 70% of the total disease burden [6]. - The obesity rate among Chinese youth is rising, with significant increases in overweight and obesity rates among school-aged children from 2010 to 2019 [7]. - The healthcare burden from obesity-related chronic diseases exceeds 300 billion yuan annually, with projections indicating that by 2030, obesity-related medical expenses could account for 22% of total health insurance expenditures [10][11]. Causes of Obesity - The rise in obesity rates is closely tied to economic development and lifestyle changes, with a positive correlation between national income and obesity prevalence [12][14]. - Since the 1980s, China's rapid economic growth and urbanization have led to decreased physical activity and increased consumption of high-calorie processed foods [14]. - The average sedentary time for Chinese individuals has reached 8.8 hours per day, while average sleep duration has decreased significantly [14]. Weight Management Initiatives - The National Health Commission has launched the "Weight Management Year" initiative, shifting the focus from treating diseases to promoting health [18]. - Investment in weight management is projected to yield long-term healthcare savings, with estimates suggesting that every yuan spent on weight management could save 3-5 yuan in medical costs [22]. - Other countries, such as the UK and Japan, have implemented innovative strategies to address rising obesity rates, including taxes on sugary drinks and mandatory waist measurements for employees [23][24]. Conclusion - Addressing obesity is crucial not only for public health but also for the sustainability of China's healthcare and social security systems, especially in the context of an aging population [25].

Core Viewpoint - Semaglutide, a GLP-1 receptor agonist, shows significant benefits for patients with type 2 diabetes and peripheral artery disease (PAD), improving both walking distance and quality of life, beyond its glucose-lowering effects [3][10][13]. Research Objectives - The study aims to analyze the efficacy of semaglutide in improving functionality in type 2 diabetes patients with PAD, focusing on whether the effects are consistent across different clinical characteristics [5]. Research Methodology - The STRIDE trial included 792 patients with symptomatic PAD and type 2 diabetes, using a randomized, double-blind design over 52 weeks, comparing semaglutide treatment to a placebo [7]. Key Assessment Indicators - The primary endpoint was the improvement in maximum walking distance (MWD) after 52 weeks, with supplementary assessments on pain-free walking distance (PFWD) [9]. Research Results - Semaglutide significantly improved both MWD and PFWD across various patient characteristics, indicating a stable efficacy regardless of factors such as diabetes duration, body mass index (BMI), and blood glucose control [10][12]. - The average weight loss was 4.09 kg, and HbA1c levels decreased by 0.99%, but the benefits for PAD may operate through independent mechanisms [11][12]. Safety Profile - The safety of semaglutide was confirmed, with adverse event rates comparable to the placebo group, and no new safety concerns were identified [13]. Conclusion - Semaglutide is a promising treatment option for type 2 diabetes patients with PAD, demonstrating efficacy beyond traditional mechanisms, including improvements in endothelial function and microcirculation [16].

Core Viewpoint - The approval of Eli Lilly's GLP-1 drug Tirzepatide (brand name: Mounjaro) by the National Medical Products Administration of China for a new indication in treating adult Type 2 Diabetes Mellitus (T2DM) patients highlights its potential to improve blood sugar control when used in conjunction with insulin and lifestyle modifications [1][3]. Group 1 - The new indication for Tirzepatide aims to provide a safe and effective treatment option for T2DM patients who have a long disease course and have not achieved adequate blood sugar control despite insulin therapy [3]. - Tirzepatide has demonstrated significant advantages in blood sugar control, weight reduction, and metabolic improvement since its market launch [3]. Group 2 - The "GLP-1 Club" has established a network of hundreds of professionals, creating a premier platform for industry insights related to the GLP-1 sector [5]. - The club offers various resources, including academic promotions and consulting services, to support the GLP-1 community [6].

整理 | GLP1减重宝典内容团队 反式脂肪和饱和脂肪 含有大量反式脂肪和饱和脂肪的食物，如全脂牛奶、多脂奶油、全脂奶酪、黄油、冰淇淋和大多数红肉，会加重胃肠不 适，影响药物效果。建议选择健康的脂肪来源，如橄榄油、坚果和含脂肪少的鱼类。 高糖食物 高糖食品，如酱汁食物、烘焙食品、冷冻即食食品、糖果、苏打水、奶茶、果汁、甜点等，可能与药物的效果相冲突，尤其对糖尿病 患者来说，过量糖分的摄入会导致血糖剧烈波动。服用司美格鲁肽期间，应严格控制甜食的摄入。 减肥药"司美格鲁肽"已在中国正式上市。随着其广泛进入医疗机构，相关的减重门诊和内分泌门诊的咨询量也逐渐增加。 此前在采访中，上海市第六人民医院减重代谢外科的韩晓东医生就曾指出，诺和盈有严格的适应症，建议有减重需求的肥胖症患者到正规医疗 机构进行专业评估和诊断，以制定科学的减重治疗方案。 减重药物的使用需要规范化管理，光靠药物'躺瘦'很难，单靠药物很难实现有效减 重。生活方式的改变同样至关重要，用药也需调整饮食。 韩晓东强调，减重药物应在有专业资质的医生指导下使用，确保其合理且有效。因 此，大家应理性看待减重药物的效果，避免过度依赖。 ▍用药期间的饮食建议 在服用司 ...